These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 18260867)
1. [Von Willebrand factor and soluble P-selectin in patients with non ST-Elevation acute coronary syndrome during treatment with glycoprotein IIb/IIIa antagonist eptifibatide]. Mazaev AA; Naĭmushin IaA; Khaspekova SG; Golubeva NV; Ruda MIa; Mazurov AV Kardiologiia; 2007; 47(6):4-9. PubMed ID: 18260867 [TBL] [Abstract][Full Text] [Related]
2. Eptifibatide does not suppress the increase of inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. Mazaev AA; Naimushin YA; Masenko VP; Ruda MY; Mazurov AV J Thromb Thrombolysis; 2009 Feb; 27(2):146-53. PubMed ID: 18163196 [TBL] [Abstract][Full Text] [Related]
3. [Glycoprotein IIb/IIIa antagonist eptifibatide in acute coronary syndrome without elevation of ST segment]. Mazaev AA; Naĭmushin IaA; Ruda MIa Kardiologiia; 2006; 46(3):49-55. PubMed ID: 16710256 [TBL] [Abstract][Full Text] [Related]
4. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). Cornel JH; Tricoci P; Lokhnygina Y; Moliterno DJ; Wallentin L; Armstrong PW; Aylward PE; Clare RM; Chen E; Leonardi S; Van de Werf F; White HD; Held C; Strony J; Mahaffey KW; Harrington RA Am J Cardiol; 2015 May; 115(10):1325-32. PubMed ID: 25776457 [TBL] [Abstract][Full Text] [Related]
5. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type]. Galli M; Maggioni AP; Vassanelli C; Tavazzi L Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377 [TBL] [Abstract][Full Text] [Related]
6. Early versus delayed, provisional eptifibatide in acute coronary syndromes. Giugliano RP; White JA; Bode C; Armstrong PW; Montalescot G; Lewis BS; van 't Hof A; Berdan LG; Lee KL; Strony JT; Hildemann S; Veltri E; Van de Werf F; Braunwald E; Harrington RA; Califf RM; Newby LK; N Engl J Med; 2009 May; 360(21):2176-90. PubMed ID: 19332455 [TBL] [Abstract][Full Text] [Related]
7. Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial. Wang TY; White JA; Tricoci P; Giugliano RP; Zeymer U; Harrington RA; Montalescot G; James SK; Van de Werf F; Armstrong PW; Braunwald E; Califf RM; Newby LK Circulation; 2011 Feb; 123(7):722-30. PubMed ID: 21300952 [TBL] [Abstract][Full Text] [Related]
9. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes. Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862 [TBL] [Abstract][Full Text] [Related]
10. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial. Zeymer U; Margenet A; Haude M; Bode C; Lablanche JM; Heuer H; Schröder R; Kropff S; Bourkaib R; Banik N; Zahn R; Teiger E J Am Coll Cardiol; 2010 Aug; 56(6):463-9. PubMed ID: 20670755 [TBL] [Abstract][Full Text] [Related]
11. Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy. Pride YB; Mohanavelu S; Zorkun C; Kunadian V; Giugliano RP; Newby LK; Braunwald E; Califf RM; Harrington RA; Gibson CM; JACC Cardiovasc Interv; 2012 Sep; 5(9):927-35. PubMed ID: 22995880 [TBL] [Abstract][Full Text] [Related]
12. Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial). Kunadian V; Giugliano RP; Newby LK; Zorkun C; Guo J; Bagai A; Montalescot G; Braunwald E; Califf RM; Van de Werf F; Armstrong PW; Harrington R; Gibson CM Am J Cardiol; 2014 Apr; 113(8):1297-305. PubMed ID: 24607027 [TBL] [Abstract][Full Text] [Related]
13. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial. Deibele AJ; Jennings LK; Tcheng JE; Neva C; Earhart AD; Gibson CM Circulation; 2010 Feb; 121(6):784-91. PubMed ID: 20124127 [TBL] [Abstract][Full Text] [Related]
14. Routine upstream versus selective downstream administration of glycoprotein IIb/IIIa inhibitors in patients with non-ST-elevation acute coronary syndromes: a meta-analysis of randomized trials. Sciahbasi A; Biondi-Zoccai G; Romagnoli E; Valgimigli M; Rasoul S; van't Hof A; Lioy E; Stone GW Int J Cardiol; 2012 Mar; 155(2):243-8. PubMed ID: 21035214 [TBL] [Abstract][Full Text] [Related]
15. Increased reperfusion by glycoprotein IIb/IIIa receptor antagonist administration in case of unsuccessful and failed thrombolysis in patients with acute myocardial infarction: a pilot study. Di Pasquale P; Sarullo FM; Cannizzaro S; Vitrano MG; Giubilato A; Scalzo S; Giambanco F; Paterna S Ital Heart J; 2001 Oct; 2(10):751-6. PubMed ID: 11721719 [TBL] [Abstract][Full Text] [Related]